EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT

Akil A. Merchant, Aparna Jorapur, Amy McManus, Ren Liu, Valery Krasnoperov, Parvesh Chaudhry, Mohan Singh, Lisa Harton, Mary Agajanian, Miriam Kim, Timothy J. Triche, Brian J. Druker, Jeffrey W. Tyner, Parkash S. Gill

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

EPHB4, an ephrin type B receptor, is implicated in the growth of several epithelial tumors and is a promising target in cancer therapy; however, little is known about its role in hematologic malignancies. In this article, we show that EPHB4 is highly expressed in;30% of acute myeloid leukemia (AML) samples. In an unbiased RNA interference screen of primary leukemia samples, we found that EPHB4 drives survival in a subset of AML cases. Knockdown of EPHB4 inhibits phosphatidylinositol 3-kinase/AKT signaling, and this is accompanied by a reduction in cell viability, which can be rescued by a constitutively active form of AKT. Finally, targeting EPHB4 with a highly specific monoclonal antibody (MAb131) is effective against AML in vitro and in vivo. EPHB4 is therefore a potential target in AML with high EPHB4 expression.

Original languageEnglish (US)
Pages (from-to)1635-1644
Number of pages10
JournalBlood Advances
Volume1
Issue number20
DOIs
StatePublished - Sep 12 2017

Fingerprint

Acute Myeloid Leukemia
Cell Survival
Leukemia
Eph Family Receptors
Phosphatidylinositol 3-Kinase
Hematologic Neoplasms
Therapeutics
RNA Interference
Neoplasms
Monoclonal Antibodies
Growth

ASJC Scopus subject areas

  • Hematology

Cite this

Merchant, A. A., Jorapur, A., McManus, A., Liu, R., Krasnoperov, V., Chaudhry, P., ... Gill, P. S. (2017). EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Advances, 1(20), 1635-1644. https://doi.org/10.1182/bloodadvances.2017005694

EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. / Merchant, Akil A.; Jorapur, Aparna; McManus, Amy; Liu, Ren; Krasnoperov, Valery; Chaudhry, Parvesh; Singh, Mohan; Harton, Lisa; Agajanian, Mary; Kim, Miriam; Triche, Timothy J.; Druker, Brian J.; Tyner, Jeffrey W.; Gill, Parkash S.

In: Blood Advances, Vol. 1, No. 20, 12.09.2017, p. 1635-1644.

Research output: Contribution to journalArticle

Merchant, AA, Jorapur, A, McManus, A, Liu, R, Krasnoperov, V, Chaudhry, P, Singh, M, Harton, L, Agajanian, M, Kim, M, Triche, TJ, Druker, BJ, Tyner, JW & Gill, PS 2017, 'EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT', Blood Advances, vol. 1, no. 20, pp. 1635-1644. https://doi.org/10.1182/bloodadvances.2017005694
Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P et al. EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Advances. 2017 Sep 12;1(20):1635-1644. https://doi.org/10.1182/bloodadvances.2017005694
Merchant, Akil A. ; Jorapur, Aparna ; McManus, Amy ; Liu, Ren ; Krasnoperov, Valery ; Chaudhry, Parvesh ; Singh, Mohan ; Harton, Lisa ; Agajanian, Mary ; Kim, Miriam ; Triche, Timothy J. ; Druker, Brian J. ; Tyner, Jeffrey W. ; Gill, Parkash S. / EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. In: Blood Advances. 2017 ; Vol. 1, No. 20. pp. 1635-1644.
@article{9a5dc3c06c064f948dc825d2f2009129,
title = "EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT",
abstract = "EPHB4, an ephrin type B receptor, is implicated in the growth of several epithelial tumors and is a promising target in cancer therapy; however, little is known about its role in hematologic malignancies. In this article, we show that EPHB4 is highly expressed in;30{\%} of acute myeloid leukemia (AML) samples. In an unbiased RNA interference screen of primary leukemia samples, we found that EPHB4 drives survival in a subset of AML cases. Knockdown of EPHB4 inhibits phosphatidylinositol 3-kinase/AKT signaling, and this is accompanied by a reduction in cell viability, which can be rescued by a constitutively active form of AKT. Finally, targeting EPHB4 with a highly specific monoclonal antibody (MAb131) is effective against AML in vitro and in vivo. EPHB4 is therefore a potential target in AML with high EPHB4 expression.",
author = "Merchant, {Akil A.} and Aparna Jorapur and Amy McManus and Ren Liu and Valery Krasnoperov and Parvesh Chaudhry and Mohan Singh and Lisa Harton and Mary Agajanian and Miriam Kim and Triche, {Timothy J.} and Druker, {Brian J.} and Tyner, {Jeffrey W.} and Gill, {Parkash S.}",
year = "2017",
month = "9",
day = "12",
doi = "10.1182/bloodadvances.2017005694",
language = "English (US)",
volume = "1",
pages = "1635--1644",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT

AU - Merchant, Akil A.

AU - Jorapur, Aparna

AU - McManus, Amy

AU - Liu, Ren

AU - Krasnoperov, Valery

AU - Chaudhry, Parvesh

AU - Singh, Mohan

AU - Harton, Lisa

AU - Agajanian, Mary

AU - Kim, Miriam

AU - Triche, Timothy J.

AU - Druker, Brian J.

AU - Tyner, Jeffrey W.

AU - Gill, Parkash S.

PY - 2017/9/12

Y1 - 2017/9/12

N2 - EPHB4, an ephrin type B receptor, is implicated in the growth of several epithelial tumors and is a promising target in cancer therapy; however, little is known about its role in hematologic malignancies. In this article, we show that EPHB4 is highly expressed in;30% of acute myeloid leukemia (AML) samples. In an unbiased RNA interference screen of primary leukemia samples, we found that EPHB4 drives survival in a subset of AML cases. Knockdown of EPHB4 inhibits phosphatidylinositol 3-kinase/AKT signaling, and this is accompanied by a reduction in cell viability, which can be rescued by a constitutively active form of AKT. Finally, targeting EPHB4 with a highly specific monoclonal antibody (MAb131) is effective against AML in vitro and in vivo. EPHB4 is therefore a potential target in AML with high EPHB4 expression.

AB - EPHB4, an ephrin type B receptor, is implicated in the growth of several epithelial tumors and is a promising target in cancer therapy; however, little is known about its role in hematologic malignancies. In this article, we show that EPHB4 is highly expressed in;30% of acute myeloid leukemia (AML) samples. In an unbiased RNA interference screen of primary leukemia samples, we found that EPHB4 drives survival in a subset of AML cases. Knockdown of EPHB4 inhibits phosphatidylinositol 3-kinase/AKT signaling, and this is accompanied by a reduction in cell viability, which can be rescued by a constitutively active form of AKT. Finally, targeting EPHB4 with a highly specific monoclonal antibody (MAb131) is effective against AML in vitro and in vivo. EPHB4 is therefore a potential target in AML with high EPHB4 expression.

UR - http://www.scopus.com/inward/record.url?scp=85055592492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055592492&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2017005694

DO - 10.1182/bloodadvances.2017005694

M3 - Article

AN - SCOPUS:85055592492

VL - 1

SP - 1635

EP - 1644

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 20

ER -